Stay updated on Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a clinical trial testing the effectiveness of combining standard chemotherapy with PD-1 antibody, pembrolizumab, and FAK inhibitor, defactinib, for resectable pancreatic cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:12.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed description of eligibility criteria, including examples such as general health condition or prior treatments, and directs users to 'Learn About Studies' for more information on clinical research.
    Difference
    27%
    Check dated 2024-05-22T20:54:06.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:57:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page.